secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0000879169-23-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs
------------------------------------------------------------------------------

- Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).
- Raises Jakafi FY 2023 revenue guidance low end to $2.58-2.63B (from $2.55-2.63B).
- Two pivotal trials met endpoints: ruxolitinib cream in pediatric AD (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201).
- CSO Dr. Dashyant Dhanak leaving effective Aug 2, 2023; oversaw 15+ IND filings during tenure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/0000879169-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/incy-20230801.htm
  HTML page:      https://secwatch.observer/filing/0000879169-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer